Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Updated European Association of Urology Guidelines on Renal Cell Carcinoma : Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma

Bedke, Jens ; Albiges, Laurence ; Capitanio, Umberto ; Giles, Rachel H. ; Hora, Milan ; Lam, Thomas B. ; Ljungberg, Börje ; Marconi, Lorenzo ; Klatte, Tobias and Volpe, Alessandro , et al. (2021) In European Urology 79(3). p.339-342
Abstract

Longer follow-up and new trial data from phase 3 randomised controlled trials investigating immune checkpoint blockade (PD-1 or its ligand PD-L1) in advanced clear-cell renal cell carcinoma (RCC) have recently become available. The CheckMate 9ER trial demonstrated an improved progression-free survival (PFS) and overall survival (OS) benefit for the combination of cabozantinib plus nivolumab. A Keynote-426 update demonstrated an ongoing OS benefit for pembrolizumab plus axitinib in the intention-to-treat population, with a PFS benefit seen across all International Metastatic Database Consortium (IMDC) subgroups, while an update of CheckMate 214 confirmed the long-term benefit of ipilimumab plus nivolumab in IMDC intermediate and poor... (More)

Longer follow-up and new trial data from phase 3 randomised controlled trials investigating immune checkpoint blockade (PD-1 or its ligand PD-L1) in advanced clear-cell renal cell carcinoma (RCC) have recently become available. The CheckMate 9ER trial demonstrated an improved progression-free survival (PFS) and overall survival (OS) benefit for the combination of cabozantinib plus nivolumab. A Keynote-426 update demonstrated an ongoing OS benefit for pembrolizumab plus axitinib in the intention-to-treat population, with a PFS benefit seen across all International Metastatic Database Consortium (IMDC) subgroups, while an update of CheckMate 214 confirmed the long-term benefit of ipilimumab plus nivolumab in IMDC intermediate and poor risk patients. The RCC Guidelines Panel continues to recommend these tyrosine kinase inhibitors + immunotherapy (IO) combination across IMDC risk groups in advanced first-line RCC and dual immunotherapy of ipilimumab and nivolumab in IMDC intermediate and poor risk. Patient summary: New data from trials of immune checkpoint inhibitors for advanced kidney cancer confirm a survival benefit with the combination of cabozantinib plus nivolumab and pembrolizumab plus axitinib and ipilimumab plus nivolumab. These combination therapies are recommended as first-line treatment for advanced kidney cancer.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Cabozantinib, Clear cell, First line, Nivolumab, Renal cell carcinoma, Systemic therapy, Treatment-naïve
in
European Urology
volume
79
issue
3
pages
4 pages
publisher
Elsevier
external identifiers
  • pmid:33357997
  • scopus:85099364654
ISSN
0302-2838
DOI
10.1016/j.eururo.2020.12.005
language
English
LU publication?
yes
id
cc847aa3-bf64-4ce1-872e-008b8e244c37
date added to LUP
2021-12-28 13:19:12
date last changed
2023-09-27 08:12:15
@article{cc847aa3-bf64-4ce1-872e-008b8e244c37,
  abstract     = {{<p>Longer follow-up and new trial data from phase 3 randomised controlled trials investigating immune checkpoint blockade (PD-1 or its ligand PD-L1) in advanced clear-cell renal cell carcinoma (RCC) have recently become available. The CheckMate 9ER trial demonstrated an improved progression-free survival (PFS) and overall survival (OS) benefit for the combination of cabozantinib plus nivolumab. A Keynote-426 update demonstrated an ongoing OS benefit for pembrolizumab plus axitinib in the intention-to-treat population, with a PFS benefit seen across all International Metastatic Database Consortium (IMDC) subgroups, while an update of CheckMate 214 confirmed the long-term benefit of ipilimumab plus nivolumab in IMDC intermediate and poor risk patients. The RCC Guidelines Panel continues to recommend these tyrosine kinase inhibitors + immunotherapy (IO) combination across IMDC risk groups in advanced first-line RCC and dual immunotherapy of ipilimumab and nivolumab in IMDC intermediate and poor risk. Patient summary: New data from trials of immune checkpoint inhibitors for advanced kidney cancer confirm a survival benefit with the combination of cabozantinib plus nivolumab and pembrolizumab plus axitinib and ipilimumab plus nivolumab. These combination therapies are recommended as first-line treatment for advanced kidney cancer.</p>}},
  author       = {{Bedke, Jens and Albiges, Laurence and Capitanio, Umberto and Giles, Rachel H. and Hora, Milan and Lam, Thomas B. and Ljungberg, Börje and Marconi, Lorenzo and Klatte, Tobias and Volpe, Alessandro and Abu-Ghanem, Yasmin and Dabestani, Saeed and Fernández-Pello, Sergio and Hofmann, Fabian and Kuusk, Teele and Tahbaz, Rana and Powles, Thomas and Bex, Axel}},
  issn         = {{0302-2838}},
  keywords     = {{Cabozantinib; Clear cell; First line; Nivolumab; Renal cell carcinoma; Systemic therapy; Treatment-naïve}},
  language     = {{eng}},
  number       = {{3}},
  pages        = {{339--342}},
  publisher    = {{Elsevier}},
  series       = {{European Urology}},
  title        = {{Updated European Association of Urology Guidelines on Renal Cell Carcinoma : Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma}},
  url          = {{http://dx.doi.org/10.1016/j.eururo.2020.12.005}},
  doi          = {{10.1016/j.eururo.2020.12.005}},
  volume       = {{79}},
  year         = {{2021}},
}